A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.

• Attention Deficit Hyperactivity Disorder (ADHD)
• Attention Deficit Hyperactivity Disorder

• Drug: methylphenidate HCl ERCT
  methylphenidate HCl ERCT
• Drug: Placebo
  Placebo to Match Quillichew ERCT

• Active Comparator: Quillichew ERCT
  Quillichew ERCT
  Intervention: Drug: methylphenidate HCl ERCT
• Placebo Comparator: Placebo to match Quillichew ERCT
  Placebo to match Quillichew ERCT
  Intervention: Drug: Placebo

Inclusion Criteria:

1. Male or female child 4-5 years of age at baseline.
2. Signed and dated informed consent document.
3. Meets DSM-V criteria for ADHD based on the K-SADS-PL.
4. ADHD RS-IV Preschool Home Version score at Screening and Baseline >/= 90th percentile for gender and age in >/=1 of the following: hyperactive-impulsive subscale, inattentive subscale, or total score.
5. Peabody Picture Vocabulary Test 4 (PPVT4)Standard Score >/=70.
6. Child Global Assessment Scale (CGAS) score </= 55.

Exclusion Criteria:

1. Treated with atomoxetine within 30 days prior to the Baseline.
2. Received any investigational products or devices within 30 days prior to the Baseline visit.
3. History of stimulant nonresponse, intolerability or hypersensitivity to any dose of Quillichew ERCT or other stimulant.
4. An intelligence quotient (IQ) <70.
5. History of acute or chronic medical or psychiatric condition or cardiac or laboratory abnormality.
6. Less than 5th percentile for height or weight at Screening.
7. History of recent clinically significant self-harming behaviors.